ERCC1在鼻咽癌组织中的表达及其与顺铂化疗敏感性的关系

Expression of ERCC1 in nasopharyngeal carcinoma tissues and its relationship with chemosensitivity to cisplatin

目的:探讨核苷酸切除修复交叉互补基因1(excision repair cross-complementing 1,ERCC1)在鼻咽癌(nasopharyn-geal carcinoma,NPC)组织中的表达及其与顺铂化疗敏感性的关系。方法:选取广西南溪山医院2006年6月至2008年6月确诊的82例中晚期NPC患者,接受顺铂+5-FU的基础化疗加放疗,应用免疫组化法检测NPC癌组织中ERCC1蛋白的表达及其中的34例患者癌旁上皮组织(对照组)中ERCC1蛋白的表达。结果:NPC癌旁上皮组织中ERCC1的阳性率为88.2%,显著高于NPC癌组织中ERCC1的阳性率63.4%(P<0.05)。ERCC1表达与NPC患者年龄有关(P<0.05),而与性别、T分期、N分期、M分期无关(P>0.05)。ERCC1蛋白表达阳性的NPC患者化疗有效率为36.5%,ERCC1阴性患者化疗有效率为63.3%,两者差异有统计学意义(P<0.05)。结论:ERCC1在中晚期NPC癌组织中低表达,ERCC1表达与顺铂+5-FU方案的疗效呈负相关,检测ERCC1表达有助于预测NPC患者对顺铂化疗的敏感性。

Objective ：To examine the expression of ERCC1 （excision repair cross-complementing 1, ERCC1 ） in nasopharyngeal carcinoma （NPC） tissues and its relationship with chemosensitivity to cisplatin-based chemotherapy. Methods： Eighty-two patients with advanced NPC, who were diagnosed at Nanxisan hospital of Guangxizhuang autonomous region from June 2006 to June 2008, were treated with cisplatin ＋5-FU regimen. The expression of ERCC1 in 82 nasopharyngeal carcinoma （NPC） tissues and in 34 adjacent normal tissues was detected by immunohistochemistry assay. Results： The positive rate of ERCC1 expression in NPC adjacent normal tissues was significantly higher than that in NPC tissues （88.2% vs 63.4%, P 〈0.05）. Expression of ERCC1 in NPC was positively correlated with patients＇ age, but not with gender, T stage, N stage and M stage （P 〉0.05）. The efficacy rate of cisplatin-based chemotherapy in ERCC1 positive NPC patients was significantly higher than that in ERCC1 negative patients （63.3% vs 36.5%, P 〈 0.05）. Conclusion： ERCC1 is lowly expressed in advanced NPC tissues; its expression is negatively correlated with the chemosensitivity to cisplatin ＋ 5-FU regimen. ERCC1 can be used to predict the sensitivity of NPC patients to cisplatin-based chemotherapy.